To optimally serve patients, it is beneficial for clinicians to be aware of updates in prescription drug labeling which may influence their practice. Pharmacogenomic biomarker information is currently included in various areas of the prescription package inserts (PI) of many medications, including neuropsychiatric drug therapies, to aid provision of personalized medicine. Personalized medicine includes incorporating a patient's genetic variables that influence drug selection and dosing into drug therapy, and tailoring treatment for optimal response and minimal adverse reactions.1 Genetic variables may influence both pharmacokinetic and pharmacodynamic responses to drug therapy. Personalized medicine allows the clinician to choose the most effective and safest therapy initially. Please see the summary (Table I on next page) of the neuropsychiatric pharmacogenomic biomarkers detailed in prescription package inserts. Complete drug labeling information for specific drugs may be found on the frequently updated U.S. Food and Drug Administration website.2 Clinicians are highly encouraged to review data in prescription package inserts of the pharmacotherapies they commonly encounter in practice.

Table I:

Neuropsychiatric Pharmacogenomic Biomarkers Detailed in Rx Package Inserts2,3 

Neuropsychiatric Pharmacogenomic Biomarkers Detailed in Rx Package Inserts23
Neuropsychiatric Pharmacogenomic Biomarkers Detailed in Rx Package Inserts23
1.
Klein
TE
,
Chang
JT
,
Cho
MK
,
Easton
KL
,
Fergerson
R
,
Hewett
M
et al.
Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base
.
Pharmacogenomics J
.
2001
;
1
(
3
):
167
70
.
PubMed PMID: 11908751
.
2.
U.S. Food and Drug Administration
.
Table of Pharmacogenomic Biomarkers in Drug Labels
.
3.
LegalVIEW
.
Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels
.